112 related articles for article (PubMed ID: 34420939)
1. Relationship between endocrine resistance and the periods of adjuvant endocrine treatment for hormone receptor-positive, HER2-negative breast cancer.
Yamamura J; Miyamura Y; Kamigaki S; Fujita J; Osato H; Manabe H; Tanaka Y; Shinzaki W; Hahimot Y; Ito T; Komoike Y
Breast Dis; 2022; 41(1):109-114. PubMed ID: 34420939
[TBL] [Abstract][Full Text] [Related]
2. Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.
Kwa M; Li X; Novik Y; Oratz R; Jhaveri K; Wu J; Gu P; Meyers M; Muggia F; Speyer J; Iwano A; Bonakdar M; Kozhaya L; Tavukcuoglu E; Budan B; Raad R; Goldberg JD; Unutmaz D; Adams S
Breast Cancer Res Treat; 2018 Feb; 168(1):57-67. PubMed ID: 29124456
[TBL] [Abstract][Full Text] [Related]
3. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study.
Le Saux O; Lardy-Cleaud A; Frank S; Debled M; Cottu PH; Pistilli B; Vanlemmens L; Leheurteur M; Lévy C; Laborde L; Uwer L; D'hondt V; Berchery D; Lorgis V; Ferrero JM; Perrocheau G; Courtinard C; Mouret-Reynier MA; Velten M; Breton M; Parent D; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2019 Sep; 118():131-141. PubMed ID: 31330488
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
6. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
[TBL] [Abstract][Full Text] [Related]
8. Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer.
Paplomata E; Zelnak A; Santa-Maria CA; Liu Y; Gogineni K; Li X; Moreno CS; Chen Z; Kaklamani V; O'Regan RM
Clin Breast Cancer; 2019 Jun; 19(3):188-196. PubMed ID: 30745109
[TBL] [Abstract][Full Text] [Related]
9. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
10. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial.
Malorni L; Curigliano G; Minisini AM; Cinieri S; Tondini CA; D'Hollander K; Arpino G; Bernardo A; Martignetti A; Criscitiello C; Puglisi F; Pestrin M; Sanna G; Moretti E; Risi E; Biagioni C; McCartney A; Boni L; Buyse M; Migliaccio I; Biganzoli L; Di Leo A
Ann Oncol; 2018 Aug; 29(8):1748-1754. PubMed ID: 29893790
[TBL] [Abstract][Full Text] [Related]
11. Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5.
Bago-Horvath Z; Rudas M; Singer CF; Greil R; Balic M; Lax SF; Kwasny W; Hulla W; Gnant M; Filipits M
Clin Cancer Res; 2020 Nov; 26(21):5682-5688. PubMed ID: 32546648
[TBL] [Abstract][Full Text] [Related]
12. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
13. Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer.
Corbaux P; Lardy-Cleaud A; Alexandre M; Fontanilles M; Lévy C; Viansone AA; Mailliez A; Debled M; Goncalves A; Le Du F; Lerebours F; Ferrero JM; Eymard JC; Mouret-Reynier MA; Petit T; Frenel JS; Dalenc F; Courtinard C; Chaix M; Bachelot T
Breast Cancer Res Treat; 2022 Jan; 191(1):191-207. PubMed ID: 34687411
[TBL] [Abstract][Full Text] [Related]
14. Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
Kim HK; Lee SH; Kim YJ; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Ahn JS; Im YH; Yu JH; Park YH
BMC Cancer; 2019 Jan; 19(1):84. PubMed ID: 30654765
[TBL] [Abstract][Full Text] [Related]
15. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs.
Iwamoto T; Fujisawa T; Shien T; Araki K; Sakamaki K; Sangai T; Kikawa Y; Takao S; Nishimura R; Takahashi M; Aihara T; Mukai H; Taira N
Breast Cancer; 2020 Sep; 27(5):973-981. PubMed ID: 32394413
[TBL] [Abstract][Full Text] [Related]
17. Everolimus Plus Letrozole for Treatment of Patients With HR
Safra T; Kaufman B; Kadouri L; Efrat Ben-Baruch N; Ryvo L; Nisenbaum B; Evron E; Yerushalmi R
Clin Breast Cancer; 2018 Apr; 18(2):e197-e203. PubMed ID: 29097108
[TBL] [Abstract][Full Text] [Related]
18. Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL).
Lee J; Im SA; Kim GM; Jung KH; Kang SY; Park IH; Kim JH; Ahn HK; Park YH
Cancer Res Treat; 2021 Jul; 53(3):695-702. PubMed ID: 33332933
[TBL] [Abstract][Full Text] [Related]
19. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.
Messina C; Cattrini C; Buzzatti G; Cerbone L; Zanardi E; Messina M; Boccardo F
Breast Cancer Res Treat; 2018 Nov; 172(1):9-21. PubMed ID: 30054831
[TBL] [Abstract][Full Text] [Related]
20. Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity.
Frassoldati A; Biganzoli L; Bordonaro R; Cinieri S; Conte P; Laurentis M; Mastro LD; Gori S; Lauria R; Marchetti P; Michelotti A; Montemurro F; Naso G; Pronzato P; Puglisi F; Tondini CA
Future Oncol; 2020 Feb; 16(5):129-145. PubMed ID: 31849236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
